The Genzyme OSOM Influenza A and B Flu Test Kits provide a differential diagnosis of Influenza A and Influenza B that is quick and reliable. The Genzyme OSOM Influenza A & B Test Kit is a rapid diagnostic test for the detection of influenza A and Influenza B from nasal swab specimens. Specimens used to perform the test are collected from a nasal swab and flu test results are available in as little as ten minutes that are accurate and easy to interpret.
OSOM Influenza A and B
The Genzyme OSOM Influenza A & B Test kit is an immunochromatographic assay intended for the qualitative detection of Influenza A and Influenza B viral nucleoprotein antigens from nasal swab specimens.
Product Features of the Genzyme OSOM Influenza A & B Flu Test Kits:
- Moderately Complex Test
- Differentiates between Influenza A and B
- Easy to read, 3 distinct lines
- Nasal swab specimens
- 2 extra test sticks included for external QC testing
- Less than 1 minute hands on time, results in 10 minutes
- Room temperature storage
- Shelf life of 12 months from date of manufacture
SUMMARY AND EXPLANATION OF TEST
Along with the common cold, inﬂuenza is one of the most common acute respiratory infections, producing symptoms such as headache, chills, dry cough, body aches and fever. It affects 10% – 20% of the United States population annually, resulting in more than 110,000 hospitalizations and 10,000 to 40,000 deaths.
The inﬂuenza A virus is typically more prevalent and is associated with the most serious inﬂuenza epidemics, while inﬂuenza B infections usually present milder symptoms. Diagnosis is difﬁcult because the initial symptoms can be similar to those caused by other infectious agents. Considering that the inﬂuenza virus is highly contagious, accurate diagnosis and prompt treatment of patients can have a positive effect on public health. Accurate diagnosis and the ability to distinguish between A or B antigens can also help reduce the inappropriate use of antibiotics and gives the physician the opportunity to prescribe an appropriate antiviral therapy. Initiation of antiviral therapy within 48 hours of symptom onset is recommended for more rapid reduction of symptoms and to reduce viral shedding.
PRINCIPLE OF THE TEST
The OSOM Inﬂuenza A&B Test consists of a test stick that separately detects inﬂuenza A and B. The test procedure requires the solubilization of the nucleoproteins from a swab by mixing the swab in Extraction Buffer. The test stick is then placed in the sample mixture, which then migrates along the membrane surface. If inﬂuenza A and/or B viral antigens are present in the sample, it will form a complex with mouse monoclonal IgG antibodies to inﬂuenza A and/or B nucleoproteins conjugated to colloidal gold. The complex will then be bound by another mouse anti-inﬂuenza A and/or B antibody coated on the nitrocellulose membrane. A pink to purple control line must appear in the control region of the stick for results to be valid. The appearance of a second and possibly a third light pink to purple line will appear in the test line region indicating an A, B or A and B positive result.